Earnings Call Transcript Summaries

Somany Ceramics Limited SOMANYCERA Q1FY27 📞 Audio

Filed 12 Aug 2026

Margin improvement driven by higher standalone capacity utilization (83% vs 72% last year) and JV profitability turnaround (Q1 FY27 JV profit ₹3 cr vs ₹10 cr loss last year).
FY27 volume growth guided at mid-single digits, with cautious optimism due to past overpromises.
Additional 4-5 mn sqm capacity expansion via balancing equipment across existing plants by Q4 FY27, enhancing value-added mix.
Operational efficiencies and capacity utilization are key margin levers; pricing gains are pass-through only.
Construction chemicals capacity expanded recently in South and North, with benefits expected from Q2/Q3 FY27.
New 9 mn sqm greenfield plant in South India to be operational by Q3/Q4 FY28, capex ~₹220 crore.

Grasim Industries Limited GRASIM Q1FY27 📞 Audio · Construction Materials

Filed 12 Aug 2026

VSF EBITDA roughly doubled YoY despite 4% volume decline; driven by strong pricing and product mix.
B2B e-commerce (Birla Pivot) to achieve EBITDA breakeven by FY27 exit, scaling on existing cost base.
Cement capacity increased by 8.7 MT in Q1 FY27; volumes up 12% YoY; green power mix at 45.6%.
Cement EBITDA up 12% YoY aided by volume growth and lower logistics/power costs.
Capex guidance for FY27 at Rs. 3,157 crore, 45% towards growth; Q1 spend at Rs. 375 crore.
Paints business targeting Rs. 10,000 crore revenue by FY28 with >50% YoY growth in FY27.

Pace Digitek Limited PACEDIGITK Q1FY27 📝 Transcript

Filed 12 Aug 2026

BESS capacity expanded to 5 GWh; 10 GWh plant commissioning expected by Dec 2026
EBITDA margin Q1 at 15.5%; PAT margin guidance 10.5-11%
Q1 FY27 consolidated revenue Rs.555 crore, +51.3% y-y; energy 79.5%, telecom 20.5%
FY27 revenue guidance Rs.3,200-3,400 crore; H1 revenue target 40-45% of annual
AI data center power solutions partnership with Megmeet progressing; revenue plan in next quarter
Order book strong at Rs.10,803 crore; energy Rs.8,453 crore, telecom Rs.2,350 crore

Emcure Pharmaceuticals Limited EMCURE Q1FY27 📝 Transcript · Healthcare

Filed 12 Aug 2026

Domestic organic growth impacted by Zuventus consolidation; expected to align with or exceed industry growth from Q2 onwards
Q1 FY27 revenue grew 22.8% y-y to INR 2,580 Cr; EBITDA up 25.8% to INR 508 Cr with 19.7% margin (+50 bps); PAT rose 36.2% to INR 292 Cr
FY27 guidance: low to mid-teen revenue growth, 70-100 bps EBITDA margin expansion
Gross margin around 59% in FY27 due to business mix; targeting 60-61% range long term
R&D investments at INR 90 Cr (3.5% of revenue), expected to rise to 4-5% of revenue in FY27
Net debt INR 1,103 Cr as of June 30, expected to rise due to acquisitions, net cash targeted by FY28

Inox Wind Limited INOXWIND Q1FY27 📝 Transcript · Capital Goods

Filed 12 Aug 2026

4X wind turbine prototype installation in August; commercial launch by FY26 end
Risks limited to force majeure; confident of meeting full-year guidance
Q1 FY27 consolidated revenue INR872 Cr, EBITDA INR237 Cr, PAT INR64 Cr
FY27 revenue growth guidance 75%, EBITDA margin 20-22%, H2 weighted business
Wind World India acquisition approved; completion expected Q2 FY27
Working capital and receivables expected to improve with equipment supply pivot

Inox Green Energy Services Limited INOXGREEN Q1FY27 📝 Transcript · Services

Filed 12 Aug 2026

INOX Wind Q1 FY27 consol revenue 872cr; EBITDA 237cr; PAT 64cr; pivot to equipment supply with 59% order book share
4X wind turbine prototype installation in August; commercial launch by FY26 end
Risks limited to force majeure; confident of meeting full-year guidance
Q1 FY27 INOX Green: Total income 101cr +17% y-y; EBITDA 57cr +19% y-y; PBT 54cr +74% y-y; PAT 41cr +86% y-y; Cash PAT 55cr +25% y-y
FY27 revenue growth guidance 75% with EBITDA margin 20-22%; H2 weighted business
Acquisition of Wind World India approved by NCLT; completion expected Q2 FY27; Wind World O&M portfolio ~4.5 GW

Pidilite Industries Limited PIDILITIND Q1FY27 📝 Transcript · Chemicals

Filed 12 Aug 2026

Standalone Q1 FY27 revenue grew 22.2% to INR 4,237 Cr; volume growth 11.3%
Demand remains robust despite price hikes; projects and retail waterproofing growing
Margins expected to stay within 20-24% corridor; Q1 benefited from lower-cost inventory
Consumer & Bazaar volume growth 12.2%; B2B volume growth 7.3%, exports down 8.4%
Electronics adhesives progressing; focus on consumer electronics and EV segments
Market share gains in core categories at 1.5x-2x market growth

Life Insurance Corporation Of India LICI Q1FY27 📝 Transcript · Financial Services

Filed 12 Aug 2026

Q1 FY27 profit after tax grew 22.81% y-y to 13,492 Cr; total premium income up 6.75% y-y to 127,250 Cr
Management expects margins to improve further in FY27; ULIP sales impacted by market volatility but expected to recover
Protection business growing strongly, driven mainly by individual agents; bancassurance impacted by external factors but expected to improve
Solvency ratio pre-dividend at 2.42, expected to support business growth and regulatory changes
VNB margin improved 750 bps y-y to 22.9%; VNB grew 61.32% y-y to 3,136 Cr
Non-par individual APE share rose to 32.49%; focus on margin-accretive non-par savings and protection

Greaves Cotton Limited GREAVESCOT Q1FY27 📝 Transcript · Capital Goods

Filed 12 Aug 2026

Multiple analyst queries on margin breakdown and growth outlook; management confident on 16-20% CAGR and margin targets
Q1 FY27 consolidated revenue grew 31% y-y to INR975 Cr; core business up 16% y-y
Greaves Electric Mobility volumes up 101% y-y; market share 5.6% with strong regional leadership
Margins pressured by commodity inflation and investments; price hikes and cost controls to improve margins from Q2
Energy Solutions grew 21% y-y; medium horsepower gensets up 32% y-y
Mobility Solutions grew 18% y-y; automotive engines up 36% y-y; e-powertrain progressing

Kaynes Technology India Limited KAYNES Q1FY27 📝 Transcript · Capital Goods

Filed 12 Aug 2026

Margin pressure expected due to component cost inflation and supply shortages; pricing pass-through ongoing
Space tech: 3U satellite prototype ready; launch expected mid-2027; titanium gas bottle manufacturing for ISRO and DRDO
OSAT and PCB capex INR1,200 crore spent; commercial production to start Q3 FY27; INR500 crore revenue target FY27
Capex guidance FY27: INR300 crore each for OSAT and PCB, INR250 crore for EMS; funding on track
Q1 FY27 revenue INR946 crore +40% y-y; EBITDA INR147.6 crore +31% y-y; EBITDA margin 15.6%
Strong order book INR9,000 crore; new customer wins including large EV manufacturer and global brands

PG Electroplast Limited PGEL Q1FY27 📝 Transcript · Consumer Durables

Filed 12 Aug 2026

New washing machine plant capacity 3 mn units; 70-80% utilization expected by FY28
Commodity inflation partially passed; price hikes expected from Dec quarter
Q1 FY27 consolidated revenue INR2,034 Cr +35.2% y-y; EBITDA INR156.2 Cr +12.1%, margin 7.7%; PAT INR75.3 Cr +12.9%
Operating margin expected ~8% for FY27; normalized per-unit margins anticipated
Multiple analyst queries on margin recovery, capacity ramp-up, and outsourcing trends
Refrigeration plant on track for Q4 FY27 start; anchor customer commitments secured

Capacit'e Infraprojects Limited CAPACITE Q1FY27 📝 Transcript

Filed 12 Aug 2026

Order book 13,535cr (55% public, 45% private); FY27 order inflow target 4,500-5,000cr; 1,071cr booked so far
Capex Q1 at 52.2cr; full year target 193cr; net debt expected to reduce over FY27 with target net debt-free in 8 quarters
Execution impacted by labor shortages and delayed project starts; normalized labor expected to boost H2 revenue
Q1 FY27 revenue 629cr +7% y-y; EBITDA 99cr -3%; EBITDA margin 15.7% (Q1 FY26: 17.2%); PAT 40cr (6.2% margin) vs 47cr last year
Provision of 10cr for commodity inflation; hopeful of reversal in Q3-Q4 if escalation indices improve

Transrail Lighting Limited TRANSRAILL Q1FY27 📝 Transcript · Capital Goods

Filed 12 Aug 2026

Q1 FY27 revenue grew 5% y-y to INR1,736 Cr; EBITDA INR203 Cr, margin 11.7% exceeding 11% guidance; PAT INR108 Cr, +3% y-y
FY27 revenue growth guidance maintained at 20% y-y; execution expected to improve in Q2 and Q3
Net debt increase due to working capital; expected normalization by Q2; working capital days targeted below 81
Order book INR16,035 Cr with INR400 Cr L1; tender pipeline >INR20,000 Cr for Q2/Q3
Commercial production started at Butibori tower plant; international footprint expanded to 6 continents
Interim dividend declared at INR3/share; Board approved 189,000 stock options grant

Kwality Pharmaceuticals Limited KPL Q1FY27 📝 Transcript

Filed 12 Aug 2026

Oncology revenue expected INR100-110 crores in FY27; expansion adds 45-50% capacity
Biosimilar revenue target INR600-700 crores by FY29; Keytruda launch expected end CY28
Capex INR185-195 crores planned over FY27-FY29; funded by internal accruals
FY27 revenue guidance INR700+ crores; EBITDA margin 26-27%
EBITDA margin expected to reach ~30% by FY29 with revenue growth to INR1000 crores
Hormone plant commercializing Nov 2026; INR70-80 crores revenue in FY28, INR150-200 crores in FY29

Gujarat Narmada Valley Fertilizers and Chemicals Limited GNFC Q1FY27 📝 Transcript · Chemicals

Filed 12 Aug 2026

Capex of INR300 Cr in Q1; full year target INR1,200-1,500 Cr; total projects INR2,800 Cr plus INR1,500 Cr next 2 years
TGU production and profitability significant; expected to sustain FY27 levels
Q1 FY27 profits second highest in company history after Q1 FY22
TDI, ethyl acetate, acetic acid plants down in Q1 due to cost; resumed operations in August
Kearney consulting ongoing for margin improvement; potential savings INR250-300 Cr by Q2
Energy norms for urea revised to 6.37 Gcal/MT valid for 3 years from FY25-26

Anlon Healthcare Limited AHCL Q1FY27 📝 Transcript

Filed 12 Aug 2026

Expect EBITDA margin normalization to 25-30% range by Q2/Q3 FY27 as raw material prices stabilize
Capacity expanded to 1400-1600 MT; utilization ~65-70%; new 1200 MT capacity commissioning expected Q1 FY28
Q1 FY27 consolidated revenue 87.62 Cr (+163% y-y), EBITDA 15.65 Cr, PAT 8.28 Cr
Consolidated EBITDA margin expected 25-27% for FY27; PAT margin guidance 12-13%
EBITDA margin moderated to ~17% due to raw material price surge and consolidation of Remember India Health Links
FY27 revenue guidance raised to 350-400 Cr, driven by organic growth and acquisitions

Multi Commodity Exchange of India Limited MCX Q1FY27 📝 Transcript · Financial Services

Filed 12 Aug 2026

Q1 FY27 total income grew 85% to INR752 Cr; revenue from operations up 88% to INR702 Cr
Expect continued growth in traded clients and product pipeline including indices and metals
Bank guarantee regulation impact expected gradual and limited; awaiting FPI participation expansion updates
Successful launch of Silver 100 Grams Futures contract; expanded Good Delivery Norms including silver
Electricity futures Q1 ADT INR37 Cr; market share ~55%; strong open interest growth
Client base doubled to 13.72 lakh, showing wider adoption of commodity derivatives

DEE Development Engineers Limited DEEDEV Q1FY27 📝 Transcript

Filed 11 Aug 2026

Q1 FY27 revenue 294.5cr +31.6% y-y; EBITDA 49.7cr +38.7% y-y; margin 16.9% vs 16% Q1FY26; PAT 16.1cr +22.4% y-y
FY27 revenue guidance above 1500cr; EBITDA margin target above 19%
Seamless pipe plant commissioned; expected margin improvement as utilization ramps
Multiple analyst queries on order inflow and margin trajectory; management confident on exceeding revenue guidance
Preferential issue of 300cr completed; 225cr used for debt reduction; net debt expected to reduce to 400-425cr by FY27 end
New sectors targeted: nuclear facility planned with partner agreement expected in Q2 FY27

Titan Company Limited TITAN Q1FY27 📝 Transcript · Consumer Durables

Filed 11 Aug 2026

Subsidiaries TEAL and CaratLane on growth path; margins expected to improve gradually
Stable natural diamond prices and steady studded jewellery demand
Growth drivers: market share gain, regionalization, studded jewellery, retail transformation
Jewellery division EBIT margin normalized at 10.9%, excluding customs duty and MTM gains
Exchange schemes aid customer acquisition; margin impact neutral
Watch division EBIT margin normalized at 17.8% in Q1FY27

Fortis Healthcare Limited FORTIS Q1FY27 📝 Transcript · Healthcare

Filed 11 Aug 2026

FY27 hospital EBITDA margin target 25% including ESOP cost; ESOP charge ~INR 40 Cr/qtr initially
Consolidated operating EBITDA pre-ESOP rose 15.8% to INR 568 Cr; margin 22.3% vs 22.6% in Q1 FY26
Diagnostics revenue growth guidance 12-13%, EBITDA margin 24-25%
Multiple analyst queries on ESOP impact, margin levers, and expansion plans addressed
Q1 FY27 consolidated revenue grew 17.5% y-y to INR 2,545 Cr; hospital revenue +19%, diagnostics +10.2%
Capex includes proton therapy (~INR 252 Cr) and robotic surgery investments

🎙 Transcript Summaries